Beacon Investment Advisory Services Inc. Buys 198 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Beacon Investment Advisory Services Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,186 shares of the biopharmaceutical company’s stock after acquiring an additional 198 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 1.2% of Beacon Investment Advisory Services Inc.’s holdings, making the stock its 28th largest position. Beacon Investment Advisory Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $28,579,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in REGN. International Assets Investment Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA increased its position in Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after acquiring an additional 59,769 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock valued at $525,804,000 after purchasing an additional 96,266 shares during the last quarter. Finally, TD Asset Management Inc boosted its holdings in Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after purchasing an additional 82,034 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of several research reports. Morgan Stanley reduced their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $750.22 on Monday. The company has a market capitalization of $82.44 billion, a price-to-earnings ratio of 18.57, a P/E/G ratio of 2.89 and a beta of 0.15. The firm’s 50 day simple moving average is $905.64 and its 200 day simple moving average is $1,019.64. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.